Literature DB >> 18449341

The medical management of primary sclerosing cholangitis.

Anthony Michaels1, Cynthia Levy.   

Abstract

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through inflammation and fibrosis. This ultimately leads to biliary complications including cirrhosis, cholangiocarcinoma, and eventually death. Given the uncertainty surrounding the pathogenesis of the disease, a number of different medical therapies have been studied in the treatment of PSC. However, there currently are no effective medical therapies known to halt the progression of disease. The only definitive therapy for PSC is liver transplantation. This review will primarily focus on the medical approaches that have been studied for the treatment of PSC as well as on the management of symptoms commonly associated with the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449341      PMCID: PMC2329756     

Source DB:  PubMed          Journal:  Medscape J Med        ISSN: 1934-1997


  68 in total

1.  Oral budesonide in the treatment of primary sclerosing cholangitis.

Authors:  P Angulo; K P Batts; R A Jorgensen; N A LaRusso; K D Lindor
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

2.  Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis.

Authors:  Shinichiro Tada; Hirotoshi Ebinuma; Hidetsugu Saito; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2006-04       Impact factor: 7.527

3.  Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.

Authors:  C Schramm; P Schirmacher; I Helmreich-Becker; G Gerken; K H zum Büschenfelde; A W Lohse
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

4.  Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.

Authors:  Jayant A Talwalkar; Paul Angulo; Jill C Keach; Janice L Petz; Roberta A Jorgensen; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

5.  Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.

Authors:  H J van Hoogstraten; F P Vleggaar; G J Boland; W van Steenbergen; P Griffioen; W C Hop; J van Hattum; G P van Berge Henegouwen; S W Schalm; H R van Buuren
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

Review 6.  Medical treatment of primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

7.  Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

Authors:  A W van Milligen de Wit; H Kuiper; L Camoglio; J van Bracht; E A Jones; G N Tytgat; S J van Deventer
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-02       Impact factor: 2.566

8.  A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.

Authors:  A E Bharucha; R Jorgensen; S N Lichtman; N F LaRusso; K D Lindor
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

9.  Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.

Authors:  Martti Färkkilä; Anna-Liisa Karvonen; Heimo Nurmi; Hannu Nuutinen; Matti Taavitsainen; Pekka Pikkarainen; Päivi Kärkkäinen
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

10.  A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.

Authors:  R K Sterling; J J Salvatori; V A Luketic; A J Sanyal; A S Fulcher; R T Stravitz; M J Contos; A S Mills; M L Shiffman
Journal:  Aliment Pharmacol Ther       Date:  2004-11-01       Impact factor: 8.171

View more
  5 in total

1.  Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.

Authors:  Anna Baghdasaryan; Thierry Claudel; Astrid Kosters; Judith Gumhold; Dagmar Silbert; Andrea Thüringer; Katharina Leski; Peter Fickert; Saul J Karpen; Michael Trauner
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 2.  Trust Your Gut: The Association of Gut Microbiota and Liver Disease.

Authors:  Ridda Manzoor; Weshah Ahmed; Nariman Afify; Mashal Memon; Maryam Yasin; Hamda Memon; Mohammad Rustom; Mohannad Al Akeel; Noora Alhajri
Journal:  Microorganisms       Date:  2022-05-18

3.  Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin.

Authors:  Kei Ohnuma; Osamu Hosono; Tomoki Katayose; Noritada Yoshikawa; Hiroshi Kawasaki; Takeshi Fujii; Naoki Oyaizu; Hirotoshi Tanaka; Chikao Morimoto
Journal:  Rheumatol Int       Date:  2009-09-23       Impact factor: 2.631

4.  Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: review of a historical cohort.

Authors:  M A Kotb
Journal:  Dig Dis Sci       Date:  2008-12-10       Impact factor: 3.487

Review 5.  Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management.

Authors:  Aditi Kumar; Daniel Wheatley; Amar Puttanna
Journal:  Clin Med Insights Gastroenterol       Date:  2016-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.